541 related articles for article (PubMed ID: 25996827)
1. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
[No Abstract] [Full Text] [Related]
2. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
[No Abstract] [Full Text] [Related]
3. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
4. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
5. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
[No Abstract] [Full Text] [Related]
6. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
7. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
Lüdeke I; Terheyden P; Grisanti S; Lüke M
Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
[TBL] [Abstract][Full Text] [Related]
8. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
Stefanou MI; Gepfner-Tuma I; Brendle C; Kowarik M; Meiwes A; Eigentler T; Müller A; Garbe C; Ziemann U; Tabatabai G; Forschner A
J Dtsch Dermatol Ges; 2020 Feb; 18(2):136-139. PubMed ID: 31814289
[No Abstract] [Full Text] [Related]
9. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
[TBL] [Abstract][Full Text] [Related]
10. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
[TBL] [Abstract][Full Text] [Related]
11. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
Lindsay JN; Barras M
J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
13. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
14. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
Sundaram VR; Abbas T
Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
16. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
18. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
19. Trametinib-Associated Bradycardia.
Alhazmi L; Karim MM; Al-Sarie M; Skeel R; Karim S
Am J Ther; 2019; 26(5):e657-e659. PubMed ID: 31241492
[No Abstract] [Full Text] [Related]
20. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
[Next] [New Search]